{"id":"NCT01715285","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)","officialTitle":"A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02-12","primaryCompletion":"2016-10-31","completion":"2022-02-13","firstPosted":"2012-10-26","resultsPosted":"2018-10-15","lastUpdate":"2025-02-04"},"enrollment":1209,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Neoplasms"],"interventions":[{"type":"DRUG","name":"Abiraterone acetate","otherNames":["Zytiga"]},{"type":"DRUG","name":"Prednisone","otherNames":[]},{"type":"OTHER","name":"Androgen deprivation therapy (ADT)","otherNames":[]},{"type":"DRUG","name":"Abiraterone acetate Placebo","otherNames":[]},{"type":"DRUG","name":"Prednisone Placebo","otherNames":[]}],"arms":[{"label":"Abiraterone acetate + Prednisone + ADT","type":"EXPERIMENTAL"},{"label":"Placebo + Androgen Deprivation Therapy (ADT)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have high-risk prognostic factors will benefit from the addition of abiraterone acetate plus low-dose prednisone to androgen deprivation therapy (ADT; lutenizing hormone releasing hormone \\[LHRH\\] agonists or surgical castration).","primaryOutcome":{"measure":"Radiographic Progression-Free Survival (PFS)","timeFrame":"Up to 44 months","effectByArm":[{"arm":"Abiraterone Acetate+Prednisone+ADT","deltaMin":33.02,"sd":null},{"arm":"Placebo + ADT","deltaMin":14.78,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":208,"countries":["Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Czechia","Denmark","Finland","France","Germany","Hungary","Israel","Japan","Malaysia","Mexico","Netherlands","New Zealand","Poland","Portugal","Romania","Russia","Slovakia","South Africa","South Korea","Spain","Sweden","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["36443540","35098170","34953443","34420037","31754962","30987939","30521063","29326030","28578607"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":192,"n":597},"commonTop":["Hypertension","Back Pain","Arthralgia","Alanine Aminotransferase Increased","Fatigue"]}}